NCT00307580CompletedPhase 4
Cathflo Activase (Alteplase) Pediatric Study (CAPS)
Conditions
Drugs
Trial Snapshot
- Phase
- Phase 4
- Status
- Completed
- Sponsor
- Genentech, Inc.
- Enrollment
- 300
- Primary Endpoint
- To evaluate the safety, as measured by the incidence of intracranial hemorrhage during the treatment with Cathflo Activase, in restoring function to dysfunctional CVADs in pediatric populations.
Study Overview
Brief Summary
This was a Phase IV, open-label, single-arm, multicenter trial that was to be conducted at ~60 sites in the United States. Approximately 300 pediatric subjects with dysfunctional CVADs (including catheters with valves, multiple lumens, umbilical catheters, and implanted ports) were to be treated with up to two serially instilled doses of Cathflo Activase.
Study Design
- Study Type
- Interventional
- Primary Purpose
- Treatment
Eligibility Criteria
- Ages
- — to 17 Years (Child)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Subjects had to meet the following inclusion criteria to be eligible for study entry:
- •Less than 17 years of age
- •Clinically stable
- •Occlusion of CVAD (including catheters with valves, multiple lumens, umbilical catheters, and implanted ports)
- •For subjects who weighed >= 10 kg, inability to withdraw 3 mL of blood from the CVAD
- •For subjects who weighed < 10 kg, inability to withdraw 1 mL of blood from the CVAD
- •Ability to infuse fluids at the volume necessary to instill Cathflo Activase into the CVAD
- •Written informed consent and assent (if appropriate) provided by parent or legal guardian and compliance with study assessments for the full duration of the study
Exclusion Criteria
- •Ability to withdraw blood following subject repositioning
- •CVAD insertion < 48 hours prior to enrollment
- •Selected study catheter implanted specifically for hemodialysis
- •Evidence of mechanical, non-thrombotic occlusion of the CVAD (e.g., kink in the CVAD or suture constricting the catheter)
- •Previous enrollment in this study
- •Use of fibrinolytic agent (e.g., alteplase, reteplase, tenecteplase, urokinase, streptokinase) within 24 hours of enrollment
- •At high risk for bleeding events, embolic complications (i.e., recent pulmonary embolism, deep vein thrombosis, endarterectomy, clinically significant right-to-left shunt) in the opinion of the investigator, or with known condition for which bleeding constituted a significant hazard
- •Known hypersensitivity to alteplase or any component of the formulation
Outcomes
Primary Outcomes
To evaluate the safety, as measured by the incidence of intracranial hemorrhage during the treatment with Cathflo Activase, in restoring function to dysfunctional CVADs in pediatric populations.
Secondary Outcomes
- To estimate the rate of restoration of function to dysfunctional CVADs following administration of up to two instillations of Cathflo Activase.
Investigators
Similar Trials
Completed
Phase 1
A Trial to Assess the Pharmacokinetics, Safety, and Tolerability of Centanafadine Capsules in Pediatric Subjects With Attention-deficit Hyperactivity DisorderAttention-deficit Hyperactivity DisorderNCT04786730Otsuka Pharmaceutical Development & Commercialization, Inc.50
Completed
Phase 4
Study To Describe The Safety Of 13-valent Pneumococcal Conjugate Vaccine In Children 6 To 17 Years Of Age In IndiaVaccinesNCT03777865Pfizer100
Completed
Phase 1
Safety and Efficacy Study of Asfotase Alfa in Severely Affected Infants With Hypophosphatasia (HPP)Hypophosphatasia (HPP)NCT00744042Alexion Pharmaceuticals, Inc.11
Recruiting
Not Applicable
Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid TumorsRare Unresectable or Metastatic BRAF V600E Mutation-positive Solid TumorsNCT05868629Novartis Pharmaceuticals40
Completed
Phase 4
Dupilumab in Japanese Patients With Chronic Rhinosinusitis With Nasal Polyp (SINUS-M52)Chronic Rhinosinusitis With Nasal PolypsNCT05049122Sanofi25